<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00025441</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068961</org_study_id>
    <secondary_id>SIOP-MMT-98</secondary_id>
    <secondary_id>SFOP-SIOP-MMT-98</secondary_id>
    <secondary_id>CCLG-SIOP-MMT-98</secondary_id>
    <secondary_id>EU-20126</secondary_id>
    <secondary_id>STS-1998</secondary_id>
    <nct_id>NCT00025441</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Children With Metastatic Rhabdomyosarcoma or Other Malignant Mesenchymal Tumors</brief_title>
  <official_title>MMT 98 Study For Metastatic Disease Rhabdomyosarcoma And Other Malignant Soft Tissue Sarcoma Of Childhood</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Societe Internationale d'Oncologie Pediatrique</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Cancer and Leukaemia Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Societe Francaise Oncologie Pediatrique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating&#xD;
      children with metastatic rhabdomyosarcoma or other malignant mesenchymal tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the overall survival of children with metastatic rhabdomyosarcoma or other&#xD;
           malignant mesenchymal tumors treated with one of two different chemotherapy regimens&#xD;
           based upon risk group.&#xD;
&#xD;
        -  Determine the role of low-intensity maintenance chemotherapy after intensive&#xD;
           conventional chemotherapy in standard-risk children.&#xD;
&#xD;
        -  Determine the value of a therapeutic window in high-risk children.&#xD;
&#xD;
        -  Determine the role of sequential high-dose chemotherapy with peripheral blood stem cell&#xD;
           transplantation in achieving complete response in high-risk children.&#xD;
&#xD;
        -  Determine the complete response, overall survival, and event-free survival in high-risk&#xD;
           children.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to risk group&#xD;
      (standard vs high).&#xD;
&#xD;
      Standard-risk patients:&#xD;
&#xD;
        -  Initial chemotherapy: Patients receive vincristine IV on day 1 for weeks 1-7. Patients&#xD;
           also receive dactinomycin IV on day 1 and ifosfamide IV over 1 hour on days 1-3 of week&#xD;
           1. Patients then receive carboplatin IV over 1 hour and epirubicin IV over 6 hours on&#xD;
           day 1 of week 4. Patients then receive ifosfamide IV over 1 hour and etoposide IV over 4&#xD;
           hours on days 1-3 of week 7. Treatment repeats every 8 weeks for 3 courses in the&#xD;
           absence of disease progression or unacceptable toxicity. After the second course,&#xD;
           patients with less than 50% partial response (PR) are removed from study.&#xD;
&#xD;
      Patients with parameningeal disease undergo radiotherapy 5 days a week for about 8 weeks&#xD;
      beginning at week 9.&#xD;
&#xD;
        -  Maintenance chemotherapy: Patients receive cyclophosphamide IV over 1 hour, vincristine&#xD;
           IV, and dactinomycin IV on day 1. Treatment repeats every 3 weeks for 9 courses in the&#xD;
           absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients who remain in PR at week 17 undergo radiotherapy for about 9 weeks beginning at week&#xD;
      18.&#xD;
&#xD;
      High-risk patients:&#xD;
&#xD;
        -  Initial chemotherapy: Patients receive window study drug carboplatin IV over 1 hour or&#xD;
           doxorubicin on day 1. Treatment repeats every 3 weeks for 2 courses.&#xD;
&#xD;
      Patients receive high-dose cyclophosphamide IV over 1 hour on days 1-3 of week 7. Beginning&#xD;
      on day 8, patients receive filgrastim (G-CSF) IV or subcutaneously (SC) daily until day 13.&#xD;
      Patients may undergo peripheral blood stem cell (PBSC) collection.&#xD;
&#xD;
      Patients receive high-dose etoposide IV over 24 hours on days 15-17. Beginning on day 22,&#xD;
      patients receive G-CSF IV or SC daily until day 27.&#xD;
&#xD;
      Patients receive high-dose cyclophosphamide IV over 1 hour on days 29-31. Beginning on day&#xD;
      36, patients receive G-CSF IV or SC daily until day 42. Patients may undergo PBSC collection&#xD;
      if not previously performed. Patients who achieve complete response (CR) are removed from&#xD;
      study.&#xD;
&#xD;
      Patients receive high-dose carboplatin IV over 1 hour on days 44-48. Patients undergo PBSC&#xD;
      reinfusion on day 52. Beginning on day 55, patients receive G-CSF IV or SC daily until blood&#xD;
      counts recover.&#xD;
&#xD;
        -  Maintenance chemotherapy: Patients receive maintenance chemotherapy comprising&#xD;
           cyclophosphamide, vincristine, and dactinomycin in the same manner as the standard-risk&#xD;
           patients.&#xD;
&#xD;
      Patients with parameningeal disease and those not achieving CR undergo radiotherapy beginning&#xD;
      at week 17. Patients achieving CR, unless metastatic disease is resected, undergo&#xD;
      radiotherapy beginning on week 15.&#xD;
&#xD;
      Patients are followed every 2 months for 2 years, every 3 months for 1 year, every 6 months&#xD;
      for 2 years, and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 8-30 standard-risk patients will be accrued for this study&#xD;
      within 4 years. A total of 15-75 high-risk patients will be accrued for this study within 4-5&#xD;
      years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 1998</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Ovarian Cancer</condition>
  <condition>Sarcoma</condition>
  <condition>Small Intestine Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>dactinomycin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed metastatic rhabdomyosarcoma or other malignant mesenchymal&#xD;
             tumors&#xD;
&#xD;
               -  Standard risk defined as:&#xD;
&#xD;
                    -  Less than 10 years of age&#xD;
&#xD;
                    -  No bone or bone marrow involvement&#xD;
&#xD;
               -  High risk defined as:&#xD;
&#xD;
                    -  At least 10 years of age OR&#xD;
&#xD;
                    -  Bone or bone marrow involvement&#xD;
&#xD;
          -  Diagnosed less than 8 weeks ago&#xD;
&#xD;
          -  Previously untreated disease except for initial surgery within the past 8 weeks&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  6 months to under 18 years&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior biologic therapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No prior endocrine therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Concurrent radiotherapy allowed&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heather P. McDowell, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Royal Liverpool Children's Hospital, Alder Hey</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Annabel B.M. Foot</last_name>
    <role>Study Chair</role>
    <affiliation>Bristol Royal Hospital for Children</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christophe Bergeron</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Leon Berard</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Our Lady's Hospital for Sick Children</name>
      <address>
        <city>Crumlin</city>
        <zip>12</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham Children's Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B4 6NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Royal Hospital for Children</name>
      <address>
        <city>Bristol</city>
        <state>England</state>
        <zip>BS2 8BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital at Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <state>England</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool Children's Hospital, Alder Hey</name>
      <address>
        <city>Liverpool</city>
        <state>England</state>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds Cancer Centre at St. James's University Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Children NHS Trust</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meyerstein Institute of Oncology at University College of London Hospitals</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>WIT 3AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Manchester and Manchester Children's University Hospitals NHS Trust</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M27 4HA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle Upon Tyne Hospitals NHS Trust</name>
      <address>
        <city>Newcastle-Upon-Tyne</city>
        <state>England</state>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's Medical Centre</name>
      <address>
        <city>Nottingham</city>
        <state>England</state>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <state>England</state>
        <zip>0X3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital - Sheffield</name>
      <address>
        <city>Sheffield</city>
        <state>England</state>
        <zip>S10 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <state>England</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHS Foundation Trust - Surrey</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Belfast Hospital for Sick Children</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <zip>BT12 6BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <state>Scotland</state>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Sick Children</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Sick Children</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G3 8SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Ireland</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>McDowell HP, Foot AB, Ellershaw C, Machin D, Giraud C, Bergeron C. Outcomes in paediatric metastatic rhabdomyosarcoma: results of The International Society of Paediatric Oncology (SIOP) study MMT-98. Eur J Cancer. 2010 Jun;46(9):1588-95. doi: 10.1016/j.ejca.2010.02.051. Epub 2010 Mar 24.</citation>
    <PMID>20338746</PMID>
  </results_reference>
  <verification_date>November 2001</verification_date>
  <study_first_submitted>October 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>December 3, 2013</last_update_submitted>
  <last_update_submitted_qc>December 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2013</last_update_posted>
  <keyword>chondrosarcoma</keyword>
  <keyword>small intestine leiomyosarcoma</keyword>
  <keyword>fibrosarcomatous osteosarcoma</keyword>
  <keyword>embryonal childhood rhabdomyosarcoma</keyword>
  <keyword>alveolar childhood rhabdomyosarcoma</keyword>
  <keyword>pleomorphic childhood rhabdomyosarcoma</keyword>
  <keyword>mixed childhood rhabdomyosarcoma</keyword>
  <keyword>embryonal-botryoid childhood rhabdomyosarcoma</keyword>
  <keyword>metastatic childhood soft tissue sarcoma</keyword>
  <keyword>extraosseous Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>childhood fibrosarcoma</keyword>
  <keyword>childhood synovial sarcoma</keyword>
  <keyword>childhood malignant hemangiopericytoma</keyword>
  <keyword>childhood liposarcoma</keyword>
  <keyword>childhood alveolar soft-part sarcoma</keyword>
  <keyword>childhood leiomyosarcoma</keyword>
  <keyword>childhood angiosarcoma</keyword>
  <keyword>childhood epithelioid sarcoma</keyword>
  <keyword>childhood malignant mesenchymoma</keyword>
  <keyword>stage IV uterine sarcoma</keyword>
  <keyword>uterine leiomyosarcoma</keyword>
  <keyword>ovarian sarcoma</keyword>
  <keyword>previously untreated childhood rhabdomyosarcoma</keyword>
  <keyword>childhood desmoplastic small round cell tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Rhabdomyosarcoma</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dactinomycin</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

